Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue
- 1 January 2009
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 48 (3) , 391-400
Abstract
Introduction. Our aim was to investigate the immune status of midgut carcinoid patients. Cancer patients generally display suppressed Th1-type immunity that disables mounting of an efficient anti-tumor response. However, little is known about patients with neuroendocrine midgut carcinoids. Material and methods. Circulating regulatory T cells were determined in patient blood by staining for CD4, CD25 and FoxP3 in flow cytometric analysis. T cell proliferation was measured by Alamar Blue in response to polyclonal activation and the regulatory phenotype of patient CD25+ cells was validated by allogeneic stimulation of CFSE labelled responders. Cytokine levels in patient peripheral blood were measured by ELISA and CBA. Tumor infiltrating T cells were analyzed by immunohistochemistry and immunofluorescence. Results. The results demonstrate that midgut carcinoid patients exhibit increased frequencies of circulating Tregs and patient T cells have a decreased proliferative capacity compared to healthy donors. Systemic Th1-promoting cytokines are reduced. Midgut carcinoid tumors display CD4+ and CD8+ T cell infiltration, always in the presence of regulatory CD4+FoxP3+ cells. Discussion. Midgut carcinoid patients display elevated T regulatory cell numbers and T cell dysfunction. Therapeutic strategies to overcome tumor-induced Th1 immunosuppression are required in combination with anti-tumor vaccinations.Keywords
This publication has 43 references indexed in Scilit:
- The characterization and role of regulatory T cells in immune reactionsFrontiers in Bioscience-Landmark, 2008
- International Meeting “Immunotherapy of Cancer: Challenges and Needs”Cancer Immunology, Immunotherapy, 2006
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate CancerJournal of Clinical Oncology, 2006
- Regulatory T cells, tumour immunity and immunotherapyNature Reviews Immunology, 2006
- Induction of strong and persistent MelanA/MART‐1‐specific immune responses by adjuvant dendritic cell‐based vaccination of stage II melanoma patientsInternational Journal of Cancer, 2006
- Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic MelanomaJournal of Clinical Oncology, 2005
- Immunosuppressive networks in the tumour environment and their therapeutic relevanceNature Reviews Cancer, 2005
- Dendritic Cell Vaccination in Medullary Thyroid CarcinomaClinical Cancer Research, 2004
- A listing of human tumor antigens recognized by T cellsCancer Immunology, Immunotherapy, 2001